ArticleAdvances in laboratory medicine2026
Pharmacogenetic biomarkers for predicting therapeutic response to JAK inhibitors in rheumatoid arthritis.
Article in Advances in laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging and Investigational JAK Inhibitors for Rheumatoid Arthritis: Efficacy and Safety.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Rheumatoid arthritis (RA) is a chronic inflammatory disease of immune-mediated origin. Janus kinase inhibitors (JAK inhibitors) have expanded therapeutic options in recent years; however, clinical response varies among patients, and no biomarkers are currently available to predict their efficacy. The aim of this study was to analyze the association between pharmacogenetic variants and clinical response to JAK inhibitors in patients with RA. Methods: An observational, ambispective, single-center study was conducted in adult patients diagnosed with RA and treated with JAK inhibitors. Sociodemographic and clinical characteristics were collected from electronic medical records. Five genetic variants previously associated with response to biological therapies in RA were analyzed through genotyping. Results: A total of 56 patients were included in the study. A statistically significant association was observed between the rs20575 variant of the Conclusions: This study highlights the potential of pharmacogenetics to personalize RA treatment by establishing, for the first time, that specific genetic variants involved in immune response may significantly influence the efficacy of JAK inhibitors. These findings open new perspectives for optimizing therapeutic decisions, although further studies are needed to validate them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.